Affymax, Inc.
AFFY
Other OTC0.00
USD
- -
- -
ISIN
US00826A1097
CUSIP
00826A109
Return %
Stock
S&P500
1Y
25.00
19.01
3Y
-76.19
65.48
5Y
-97.50
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jonathan Couchman
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 630 Fifth Avenue New York City NY United States of America 10020
- IPO Date
- Dec 15, 2006
- Website
- affymax.com
- Similar Companies
- Business
- Affymax, Inc. is a development-stage biopharmaceutical company primarily engaged in the development of novel peptide-based therapeutics for the treatment of serious and life-threatening conditions, particularly in the nephrology and specialty care sectors. Its core product historically included OMONTYS (peginesatide), designed to treat anemia due to chronic kidney disease in adult patients. The company focuses on peptide therapeutics intended to improve patient care by addressing unmet medical needs. Affymax operates mainly in the United States and is headquartered in New York, New York. Founded in 2001, the company had previously collaborated with Takeda Pharmaceutical Company on OMONTYS before the product's voluntary recall in 2013 due to safety concerns, leading to the termination of the partnership and withdrawal of the New Drug Application by Takeda in 2014. In recent years, Affymax has not maintained significant commercial operations or launched new products, undergoing strategic reviews and exploring alternatives following the termination of its collaboration with Takeda. The company currently does not report substantial ongoing drug development or revenue-generating activity. Its notable changes over the last 1-2 years include a lack of major product launches, partnerships, or acquisitions, reflecting a state of limited operational activity and no recent strategic expansions or new funding rounds reported publicly. Affymax remains listed on OTC markets under the ticker AFFY, with a minimal workforce and no current analyst coverage projecting future growth. The company's earlier strategic business segments involved biopharmaceutical research and development with a focus on innovation in nephrology-related therapeutics. Its target markets historically comprised healthcare providers and patients dealing with kidney disease and related anemic conditions. Despite its initial promise in peptide drug development, Affymax's present status is largely that of a minimal-operation entity without active marketed products or ongoing clinical programs as of late 2025. Overall, Affymax is a biopharmaceutical company with a concentration on peptide drug development, headquartered in New York, founded in 2001, with a legacy product OMONTYS that was recalled and collaboration ended, currently inactive in new therapeutic development or operational expansions.
Financial Analysis: Affymax (OTCMKTS:AFFY) versus Arvinas (NASDAQ:ARVN)